Conference Proceedings
Efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC) and ALK kinase domain mutations
Alice T Shaw, Jean-Francois Martini, Benjamin Besse, Todd M Bauer, Chia-Chi Lin, Ross A Soo, Gregory J Riely, Sai-Hong Ignatius Ou, Jill S Clancy, Sherry Li, Holger Thurm, Miyako Satouchi, D Ross Camidge, Steven Kao, Rita Chiari, Shirish Gadgeel, Enriqueta Felip, Benjamin J Solomon
CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2018
Abstract
Abstract BACKGROUND: Lorlatinib is a selective, potent, brain-penetrant, 3rd-generation ALK/ROS1 TKI preclinically active against most known resistance mutations. In a Ph I/II study, lorlatinib showed robust clinical activity in ALK+ advanced NSCLC pts, most of whom had CNS metastases (mets) and were pre-treated.1 To identify molecular correlates of response, we performed molecular profiling of circulating free DNA (cfDNA) and tumor tissue in pts who were previously treated with ALK tyrosine kinase inhibitor (TKI) therapy and who received the recommended Ph II dose of lorlatinib. METHODS: Samples were analyzed from pts enrolled in one of four pre-treated ALK+ ex..
View full abstract